Calcium Pyrophosphate Disease Management

Diagnosis and Clinical Features

The American College of Rheumatology suggests that CPPD presents in four distinct clinical phenotypes that determine management approach: asymptomatic chondrocalcinosis, acute CPP crystal arthritis (pseudogout), chronic CPP inflammatory arthritis, and osteoarthritis with CPPD 1
Osteoarthritis with CPPD has standard OA features with concurrent CPP crystal deposition, and may have an increased inflammatory component compared to OA alone 1, 2

The European League Against Rheumatism recommends that joint aspiration combined with intra-articular long-acting glucocorticosteroid injection is the optimal first-line treatment for acute CPP crystal arthritis, often sufficient alone 3
The American College of Rheumatology suggests that low-dose oral colchicine (0.5-1.0 mg daily) or low-dose oral NSAIDs with gastroprotection can prevent recurrent flares of acute CPP crystal arthritis 3, 4
For chronic CPP inflammatory arthritis, the European League Against Rheumatism recommends oral NSAIDs with gastroprotection and/or low-dose colchicine (0.5-1.0 mg daily) as first-line treatment, with hydroxychloroquine as the preferred second-line agent 2, 3, 5
The American College of Rheumatology recommends that management objectives and treatment options for osteoarthritis with CPPD are identical to OA without CPPD, following standard evidence-based OA guidelines, but avoiding intra-articular high molecular weight hyaluronan 2, 3, 4

The European League Against Rheumatism advises against using traditional high-dose colchicine regimens due to marked side effects, and against using intravenous colchicine due to serious toxicity risk 4
The American College of Rheumatology recommends avoiding intra-articular hyaluronan in CPPD patients, and always providing gastroprotection with NSAIDs in older patients 2, 3, 4

Patients with calcium pyrophosphate deposition disease (CPPD) of the hip who experience refractory pain or functional disability despite optimal medical therapy (including NSAIDs, colchicine, intra‑articular corticosteroids, and second‑line agents) and have radiographic evidence of structural joint damage should be referred to orthopedics for possible surgical evaluation. 6
Presence of severe structural damage on imaging that limits hip function constitutes an absolute indication for referral; total hip arthroplasty in CPPD yields outcomes comparable to those for primary osteoarthritis. 6
Age alone should not preclude consideration of total hip arthroplasty in patients with CPPD‑related hip disease. 6
When CPPD coexists with osteoarthritis, management and referral thresholds follow standard osteoarthritis guidelines, including the same criteria for arthroplasty referral. 6
In chronic CPP inflammatory arthritis of the hip, orthopedic referral is warranted if erosive changes or progressive structural damage develop despite adequate medical treatment. 7

Joint aspiration followed by intra‑articular corticosteroid injection is the optimal first‑line therapy for acute hip CPPD flares and often resolves the episode without need for further intervention. 8

Methotrexate (approximately 5–10 mg weekly) has demonstrated efficacy in reducing pain intensity and joint swelling in patients whose disease is resistant to first‑line therapies. 7